265 related articles for article (PubMed ID: 21897227)
1. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation.
Oran B; de Lima M
Curr Opin Hematol; 2011 Nov; 18(6):388-94. PubMed ID: 21897227
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A
Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
4. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies.
Bacher U; Talano JA; Bishop MR
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S62-73. PubMed ID: 22226115
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
Miyazaki T; Fujita H; Fujimaki K; Hosoyama T; Watanabe R; Tachibana T; Fujita A; Matsumoto K; Tanaka M; Koharazawa H; Taguchi J; Tomita N; Sakai R; Fujisawa S; Kanamori H; Ishigatsubo Y
Leuk Res; 2012 Aug; 36(8):998-1003. PubMed ID: 22551655
[TBL] [Abstract][Full Text] [Related]
9. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
10. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.
Elmaagacli AH; Beelen DW; Trenschel R; Schaefer UW
Bone Marrow Transplant; 2000 Jan; 25(1):91-6. PubMed ID: 10654021
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
[TBL] [Abstract][Full Text] [Related]
14. Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).
Appelbaum FR
Best Pract Res Clin Haematol; 2008 Mar; 21(1):85-92. PubMed ID: 18342816
[TBL] [Abstract][Full Text] [Related]
15. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.
Kurosawa S; Yamaguchi T; Uchida N; Miyawaki S; Usuki K; Watanabe M; Yamashita T; Kanamori H; Tomiyama J; Nawa Y; Yano S; Takeuchi J; Yakushiji K; Sano F; Uoshima N; Yano T; Nannya Y; Moriuchi Y; Miura I; Takaue Y; Fukuda T
Biol Blood Marrow Transplant; 2011 Mar; 17(3):401-11. PubMed ID: 20667478
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
Novitzky N; Thomas V; du Toit C; McDonald A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality.
Meijer E; Cornelissen JJ
Semin Oncol; 2008 Aug; 35(4):449-57. PubMed ID: 18692695
[TBL] [Abstract][Full Text] [Related]
19. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
20. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
